We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sana Biotechnology Inc (SANA) USD0.0001

Sell:$9.94 Buy:$9.95 Change: $1.44 (17.04%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $1.44 (17.04%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $1.44 (17.04%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. The Company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. Its most advanced hypoimmune product candidate is SC291, a CD19-directed allogeneic CAR T program for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). It is also developing SC262, a CD22-directed allogeneic CAR T for the treatment of NHL, CLL, and ALL, as well as SC255, a B cell maturation antigen (BCMA)-directed allogeneic CAR T, for the treatment of multiple myeloma (MM).

Contact details

188 East Blaine Street, Suite 400
United States
+1 (206) 7017914

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.81 billion
Shares in issue:
214.34 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Richard Mulligan
    Vice Chairman of the Board and Head of SanaX
  • Nathan Hardy
    Chief Financial Officer, Executive Vice President
  • Bernard Cassidy
    Executive Vice President, General Counsel, Company Secretary
  • Christian Hordo
    Executive Vice President, Chief Business Officer
  • Douglas Williams
    Executive Vice President, President - Research and Development
  • Gary Meininger
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.